Outsourcing Services: from Gene to Patient

February 18, 2020 Outsourcing Services: from Gene to Patient

CEO Frank Mathias in ChemManager Interview

Rentschler Biopharma SE has set its sights on highly ambitious goals. Our strength lies in high-quality solutions for difficult to manufacture biopharmaceuticals - right from bioprocess development, cGMP manufacturing, to product approval for over 150 clients worldwide. To differentiate our premium services, in an everchanging biopharmaceutical landscape, we have developed our Strategy 2025.

Strategy 2025 is based on megatrends shaping the society and industry of tomorrow. To achieve this vision, we will focus on geographical expansion, strong client-partnering and best-in-class innovative services in the future. We have already set these plans in motion at our first U.S. subsidiary, located in Milford, MA, within the Boston Biotech Hub. Our multiproduct production site is already on its way to becoming an unrivalled global center of excellence.

If you would like to read more about our future plans, as well as how Germany fares in the global biopharmaceutical market, read the full interview in ChemManager.

Contact Person:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
communications@rentschler-biopharma.com